Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 8/20 | 0.67 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.55 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.54 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.54 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19493363 | 1.00 | TYMP (0.67) | TYMPP2RY12ADORA1P2RY2P2RY1 | |
| SCHEMBL17304362 | 1.00 | TYMP (0.67) | TYMPP2RY12ADORA1P2RY2P2RY1 | |
| SCHEMBL7529299 | 1.00 | TYMP (0.67) | TYMPP2RY12ADORA1P2RY2P2RY1 | |
| SCHEMBL917678 | 1.00 | TYMP (0.67) | TYMPP2RY12ADORA1P2RY2P2RY1 | |
| SCHEMBL19493362 | 1.00 | TYMP (0.67) | TYMPP2RY12ADORA1P2RY2P2RY1 | |
| SCHEMBL29679722 | 1.00 | TYMP (0.67) | TYMPP2RY12ADORA1P2RY2P2RY1 | |
| SCHEMBL8386141 | 1.00 | TYMP (0.67) | TYMPP2RY12ADORA1P2RY2P2RY1 | |
| SCHEMBL7529826 | 0.99 | TYMP (0.66) | TYMPP2RY12ADORA1P2RY2P2RY1 | |
| SCHEMBL9024707 | 0.94 | TYMP (0.69) | TYMPP2RY12ADORA1P2RY2P2RY1 | |
| SCHEMBL9550751 | 0.94 | TYMP (0.69) | TYMPP2RY12ADORA1P2RY2P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308216-A1 | PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-01 | — | — | US | disclosed |
| US-10696710-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200140477-A1 | PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-05-07 | — | — | US | disclosed |
| US-10633411-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-04-28 | — | — | US | disclosed |
| US-10508129-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-12-17 | — | — | US | disclosed |
| US-10457945-B2 | UNA oligomers for therapeutics with prolonged stability | ARCTURUS THERAPEUTICS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10336786-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180237780-A1 | UNA OLIGOMERS FOR THERAPEUTICS WITH PROLONGED STABILITY | MARINA BIOTECH, INC. | 2018-08-23 | — | — | US | disclosed |
| EP-3045535-B1 | METHODS AND USES FOR THERAPEUTIC OLIGOMERS | ARCTURUS THERAPEUTICS INC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-9944929-B2 | UNA single stranded oligomers for therapeutics | ARCTURUS THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9297009-B2 | UNA oligomers targeting micro-RNA for therapeutics | ARCTURUS THERAPEUTICS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150232849-A1 | UNA DUPLEX OLIGOMERS FOR THERAPEUTICS | MARINA BIOTECH, INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150232851-A1 | UNA OLIGOMERS TARGETING MICRO-RNA FOR THERAPEUTICS | MARINA BIOTECH, INC. | 2015-08-20 | — | — | US | disclosed |
| US-9051570-B2 | UNA oligomers for therapeutics | ARCTURUS THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20130096289-A1 | HYDROXYMETHYL SUBSTITUTED RNA OLIGONUCLEOTIDES AND RNA COMPLEXES | MARINA BIOTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8314227-B2 | Hydroxymethyl substituted RNA oligonucleotides and RNA complexes | MARINA BIOTECH, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8252919-B2 | 2′-hydroxy-protected ribonucleoside derivative and production method thereof | KANEKA CORPORATION (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | KANEKA CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2258709-A1 | 2'-HYDROXYL-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND MANUFACTURING METHOD OF SAME | Kaneka Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-20100056768-A1 | HYDROXYMETHYL SUBSTITUTED RNA OLIGONUCLEOTIDES AND RNA COMPLEXES | MDRNA, INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308216-A1 | PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY | CGAS, GMPS, STING1 | TYMP 221/4885P2RY12 304/4885ADORA1 443/4885 |
| US-10457945-B2 | UNA oligomers for therapeutics with prolonged stability | NOP2, NONO, NSUN3 | TYMP 482/4885P2RY12 2234/4885ADORA1 1437/4885 |
| US-10508129-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | CGAS, GMPS, STING1 | TYMP 221/4885P2RY12 304/4885ADORA1 443/4885 |
| US-20200140477-A1 | PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY | CGAS, GMPS, STING1 | TYMP 221/4885P2RY12 304/4885ADORA1 443/4885 |
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | RNASEL, RNASEH1, NUDT1 | TYMP 183/4885P2RY12 3020/4885ADORA1 1042/4885 |
| US-10336786-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | CGAS, GMPS, STING1 | TYMP 208/4885P2RY12 291/4885ADORA1 438/4885 |
| US-20100056768-A1 | HYDROXYMETHYL SUBSTITUTED RNA OLIGONUCLEOTIDES AND RNA COMPLEXES | NSUN2, METTL16, NSUN3 | TYMP 591/4885P2RY12 3940/4885ADORA1 1054/4885 |
| US-10696710-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | CGAS, GMPS, STING1 | TYMP 221/4885P2RY12 304/4885ADORA1 443/4885 |
| US-20180237780-A1 | UNA OLIGOMERS FOR THERAPEUTICS WITH PROLONGED STABILITY | NOP2, NONO, NSUN3 | TYMP 482/4885P2RY12 2234/4885ADORA1 1437/4885 |
| US-10633411-B2 | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway | CGAS, GMPS, STING1 | TYMP 221/4885P2RY12 304/4885ADORA1 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.